Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $9.81, but opened at $10.15. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.52, with a volume of 1,111 shares.
Wall Street Analyst Weigh In
Separately, Zacks Research raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 15th. Three analysts have rated the stock with a Strong Buy rating. Based on data from MarketBeat, the stock has an average rating of “Strong Buy”.
View Our Latest Analysis on Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. Unsponsored ADR Trading Down 0.5%
The business has a 50 day moving average of $9.33 and a two-hundred day moving average of $9.65. The firm has a market cap of $16.62 billion, a P/E ratio of 10.85, a PEG ratio of 3.50 and a beta of 0.10. The company has a current ratio of 1.14, a quick ratio of 1.00 and a debt-to-equity ratio of 0.01.
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.05). The company had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.11 billion. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 37.95% and a return on equity of 14.32%. Analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.83 earnings per share for the current year.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, it has grown from a pharmaceutical wholesaler into a research-focused drugmaker. The company has a particular focus on infectious diseases, including HIV, influenza and COVID-19, and also works in areas such as pain and central nervous system disorders. Its products include Xofluza, an influenza treatment, and ensitrelvir, an oral COVID-19 antiviral marketed in Japan as Xocova.
Featured Articles
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
- Apple’s Rare Samsung Memory Plan Could Solve One Problem and Create Another
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
